Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fedratinib - Celgene

Next Previous
Drug Profile

Fedratinib - Celgene

Alternative Names: FEDR; INREBIC; SAR-302503; TG-101348

Latest Information Update: 22 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TargeGen
  • Developer Celgene Corporation; Sanofi
  • Class Antifibrotics; Antineoplastics; Phenyl ethers; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Myelofibrosis
  • Discontinued Essential thrombocythaemia; Polycythaemia vera; Solid tumours

Most Recent Events

  • 18 Dec 2019 Celgene and Impact Biomedicines initiate a phase I drug-drug interaction trial (In volunteers) in USA (PO) (NCT04231435)
  • 07 Dec 2019 Updated efficacy data from the phase II JAKARTA 2 study in Myelofibrosis presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)
  • 07 Dec 2019 Updated efficacy data from the phase III JAKARTA study in Myelofibrosis presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top